fentanyl and Depressive Disorder, Major

fentanyl has been researched along with Depressive Disorder, Major in 8 studies

Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (8)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Changes From Baseline in PHQ-9 Depression Scores.

"The Patient Health Questionnaire-9, is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression, based on participant answers. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression, respectively. The minimum possible score is 0 and the maximum possible score is 27.~The PHQ-9 and QIDS were used to assess changes in mood during the placebo intervention (first 2 weeks), and therefore results are described as changes from the inactive to the active condition." (NCT02178696)
Timeframe: From Pre to post- active placebo, and from pre to post- inactive placebo (1 week intervention)

Changes From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) Score

"This scale is a self-report measure of depression with 16 items.~Questions in the QIDS - SR-116 correlate with the nine DSM-IV symptom criterion domains, Including: Sleep disturbance (initial, middle, and late insomnia or hypersomnia) (Q 1 - 4), Sad mood (Q 5), Decrease/increase in appetite/weight (Q 6 - 9), Concentration (Q 10), Self-criticism (Q 11), Suicidal ideation (Q 12), Interest (Q 13), Energy/fatigue (Q 14), Psychomotor agitation/retardation (Q 15 - 16).~Severity of depression can be judged based on the total score: 1-5= No depression; 6-10= Mild depression; 11-15= Moderate depression; 16-20= Severe depression; 21-27= Very severe depression.~The PHQ-9 and QIDS were used to assess changes in mood during the placebo intervention (first 2 weeks), and therefore results are described as changes from the inactive to the active condition." (NCT02178696)
Timeframe: From Pre to post- active placebo, and from pre to post- inactive placebo (1 week intervention)

Changes in BOLD Response During Reward fMRI Task (Monetary Incentive Delay, MID)

% BOLD signal changes in the nucleus accumbens from the Inactive to the Active Placebo condition. (NCT02178696)
Timeframe: (90 minute fMRI scans) assessed at Weeks 1 and 2

Changes in Dopamine (D 2/3) Binding Potential During PET.

"Binding Potential= Bmax/Kd (receptor concentration/affinity). This is the most common measure of in vivo receptor binding with PET.~Striatal changes in D2/3 receptor binding potential during PET from the Inactive to the Active condition.~Positive numbers presented here represented reductions in binding potential from the inactive to the active condition." (NCT02178696)
Timeframe: (90 minute PET scan) assessed at Weeks 1 and 2

Changes in Mu-opioid Binding Potential During PET

"Binding Potential = Bmax/Kd (receptor concentration/affinity). This is the most common measure of in vivo receptor binding with positron emission tomography. Whole brain changes in mu-opioid receptors binding potential during PET from the Inactive to the Active placebo condition.~Positive numbers presented here represent reductions in binding potential from the inactive to the active condition." (NCT02178696)
Timeframe: (90 minute PET scans) assessed at Weeks 1 and 2

Hamilton Depression Rating Scale Scores

"The total score is obtained by summing the score of each item, 0-4 (symptom is absent, mild, moderate, or severe) or 0-2 (absent, slight or trivial, clearly present). For the 17-item version, scores can range from 0 to 54, with 0 meaning no depression, and 54, severe depression.~The Hamilton Depression Rating Scale was used to assess symptoms during the open label antidepressant treatment phase, so results are described as mean scores at each bi-weekly visit." (NCT02178696)
Timeframe: Screening, week 0, week 2, week 4, week 8 and week 10

Montgomery-Asberg Depression Rating Scale

"Designed in 1979 by researchers as an adjunct to the Hamilton Rating Scale for Depression (HAMD) which would be more sensitive to the changes brought on by antidepressants and other forms of treatment than the Hamilton Scale. MADRS was used to assess symptoms during the open label antidepressant treatment phase, so results are described as mean scores at each bi-weekly visit.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 where 0 is no depression and 60 is most extreme depression.~The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts~Usual cutoff points are:~0 to 6 - normal[5] /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT02178696)
Timeframe: Screening, week 0, week 2, week 4, week 8 and week 10

Trials

2 trials available for fentanyl and Depressive Disorder, Major

Other Studies

6 other studies available for fentanyl and Depressive Disorder, Major